Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097675 | 0.87 | HSD11B1 (0.44) | NPC1RAB9ASMN1; SMN2HSD11B1MAPT | |
| SCHEMBL6171466 | 0.81 | HSD11B1 (0.42) | NPC1RAB9ASMN1; SMN2HSD11B1DCTPP1 | |
| SCHEMBL6097575 | 0.80 | CYP1A2 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL31500053 | 0.80 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL23399845 | 0.75 | CNR1 (0.40) | NPC1RAB9ASMN1; SMN2HSD11B1MAPT | |
| SCHEMBL6206806 | 0.75 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL23403272 | 0.74 | CNR1 (0.47) | NPC1RAB9ASMN1; SMN2HSD11B1MAPT | |
| SCHEMBL6096840 | 0.74 | CNR2 (0.48) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL23398432 | 0.71 | POLB (0.49) | NPC1RAB9ASMN1; SMN2CNR1CNR2 | |
| SCHEMBL23402214 | 0.70 | ADORA3 (0.40) | NPC1RAB9ASMN1; SMN2HSD11B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | NPC1 2334/4885RAB9A 3940/4885SMN1; SMN2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.